2521-90-6Relevant articles and documents
Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection
Liu, Qi,Shi, Wei-Kang,Ren, Shen-Zhen,Ni, Wei-Wei,Li, Wei-Yi,Chen, Hui-Min,Liu, Pei,Yuan, Jing,He, Xiao-Su,Liu, Jia-Jia,Cao, Peng,Yang, Pu-Zhen,Xiao, Zhu-Ping,Zhu, Hai-Liang
, p. 126 - 136 (2018/07/13)
A novel series of aniline-containing hydroxamic acids were designed, synthesized and evaluated as anti-virulence agents for the treatment of gastritis and gastric ulcer caused by Helicobacter pylori. In vitro enzyme-based screen together with in vivo assays and structure?activity relationship (SAR) studies led to the discovery of three potent urease inhibitors 3-(3,5-dichlorophenylamino)–N-hydroxypropanamide (3a), 3-(2-chlorophenylamino)–N-hydroxypropanamide (3d) and 3-(2,4-dichlorophenylamino)–N-hydroxypropanamide (3n). Compounds 3a, 3d and 3n showed excellent urease inhibition with IC50 values 0.043 ± 0.005, 0.055 ± 0.008 and 0.018 ± 0.002 μM, and significantly depressed gastritis developing at the dose of 32 mg/kg b. i.d with eradication rates of H. pylori reaching 92.3, 84.6 and 100%, respectively. Preliminary safety studies (acute toxicity in mice) disclosed that 3a, 3d and 3n was well-tolerated in KM mice with LD50s of 2982.8, 3349.4 and 3126.9 mg/kg, respectively. Collectively, the data obtained in this study indicate that 3a, 3d and 3n, in particular 3n, could considered as promising candidates for the potential treatment of H. pylori caused gastritis and gastric ulcer, and hence merit further studies.
Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor
Gallant, Michel,Belley, Michel,Carriere, Marie-Claude,Chateauneuf, Anne,Denis, Danielle,Lachance, Nicolas,Lamontagne, Sonia,Metters, Kathleen M.,Sawyer, Nicole,Slipetz, Deborah,Truchon, Jean Francois,Labelle, Marc
, p. 3813 - 3816 (2007/10/03)
Potent and selective ligands for the human EP3 prostanoid receptor are described. Triaryl compounds bearing an ortho-substituted propionic acid moiety were identified as potent EP3 antagonists based on the SAR described herein. The binding affinities of key compound on all eight human prostanoid receptors is reported.
